Wesley Yip, MD, on Clinical Implications of New Findings on Neoadjuvant Chemotherapy for Urothelial Carcinoma

Posted: Wednesday, March 16, 2022

Wesley Yip, MD, of Memorial Sloan Kettering Cancer Center, discusses new trial results suggesting a benefit to neoadjuvant gemcitabine and cisplatin given prior to nephroureterectomy for patients with high-grade upper tract urothelial carcinoma, and what that could mean for clinical practice.